Objective: The aim of this study was to determine the degree of association of BRCA1 promoter methylation with breast cancer in Asia. Methods: The study sample for the present meta-analysis was provided by published research articles on associations of BRCA1 promoter methylation with breast cancer in Asia accessed through databases on PubMed, ProQuest and EBSCO published between 1997 and November 2017. Pooled odds ratios (OR) were calculated with fixed and random-effect models. Data were processed using Review Manager 5.3 (RevMan 5.3). Results: Of a total of 475 articles, 11 studies were included in our systematic review with meta-analysis of relevant data. The results showed a highly significant association between BRCA1 promoter methylation with breast cancer in Asia (OR = 8.78 [95% CI 4.15-18.56, p < 0.00001]). Conclusion: This analysis confirmed association between BRCA1 promoter methylation and breast cancer in Asia. BRCA1 promoter assessment might be a predictive or diagnostic aid for breast cancer prediction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031799 | PMC |
| http://dx.doi.org/10.22034/APJCP.2018.19.4.885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers.
J Mol Diagn
December 2024
XING Genomic Services, Sinnamon Park, Queensland, Australia; Translational Medicine, AstraZeneca, Cambridge, United Kingdom.
Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors represent a significant advancement in the treatment of epithelial ovarian cancer, triple-negative breast cancer, pancreatic cancer, and castrate-resistant prostate cancer, and they are poised to improve treatment in an increasing number of other cancer types. PARP inhibitor efficacy as monotherapy has been primarily observed in tumors with deleterious genetic variants in genes involved in the homologous recombination repair pathway. Tumors without these variants have also been shown to respond; notably, those with hypermethylation at all alleles of the BRCA1 or RAD51C promoter can respond to PARP inhibitors.
View Article and Find Full Text PDFBRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.
Clin Epigenetics
December 2024
Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100, Alexandroupolis, Greece.
Article Synopsis
- BRCA1 and BRCA2 are tumor suppressor genes critical for repairing DNA damage through the Homologous Recombination pathway, and mutations in these genes are linked to higher risks of breast and ovarian cancers.
- Methylation of BRCA1/2 promoters can create a "BRCAness" phenotype, indicating HR deficiency in tumors, even when BRCA mutations are absent, and this methylation may serve as a valuable biomarker for predicting responsiveness to therapies like PARP inhibitors.
- The review emphasizes the need for further research into BRCA1/2 methylation as a predictive tool in cancer treatment, suggesting it could significantly enhance prognosis and treatment strategies across various cancer types.
Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a mutation.
Oncol Lett
February 2025
Department of Gynecological Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
Olaparib (AZD2281) is used as a first-line maintenance treatment for patients with ovarian cancer (OC) with a breast cancer susceptibility gene () mutation. Fatty acid binding protein 4 (FABP4) may serve an important role in cancer, but its role in olaparib-treated OC with a mutation requires further clarification. To explore the function of FABP4 and enhance the efficacy of AZD2281 in OC, cell counting kit-8, cell apoptosis, cell cycle, colony formation, cell transfection, western blotting, reverse transcription-quantitative polymerase chain reaction, chromatin immunoprecipitation, seahorse and reactive oxygen species assays were performed.
View Article and Find Full Text PDFLetter to the Editor in response to paper "BRCA1 promoter methylation in triple-negative breast cancer……" by K Daster et al.
Breast Cancer Res Treat
November 2024
Haukeland University Hospital, University of Bergen, Bergen, Norway.
Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer.
Nat Genet
December 2024
Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Germline BRCA1 mutation carriers have a high breast cancer risk, but the reasons for this increased risk are not fully understood.
- Researchers used a genetically engineered mouse model to show that the early onset of tumors in BRCA1 heterozygous mice can't be explained by the traditional "two-hit" hypothesis alone.
- Advanced techniques like single-cell RNA sequencing revealed distinct chromatin alterations in normal Brca1 heterozygous cells, hinting at epigenetic changes that might promote cancer, with specific transcription factors identified as key players in tumor development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!